Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Bristol-Myers, KAI Link For Heart Drug
May 19, 2008
| A version of this story appeared in
Volume 86, Issue 20
Bristol-Myers Squibb has signed an agreement to develop and commercialize a heart drug from the California biotechnology firm KAI Pharmaceuticals. BMS will pay KAI $25 million upfront and up to $192 million in milestone payments. It may also buy $10 million of KAI stock if the firm holds an initial public offering. The drug, KAI-9803, is an isozyme-selective inhibitor of the delta protein kinase C pathway and is designed to reduce the deleterious effects of a heart attack. It is expected to enter Phase IIb clinical trials by the end of the year.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter